top of page

600 Patients treated

Early activity detected in viral and bacterial infections

Immune effects also documented in oncology

IL-7 to Unlock the Potential
of Immunotherapies

Check Point Blockers

Provide CD4 Help
STAT5-P T       de-exhaustion
Intra-tumor infiltration

Cell Therapies
CAR T Specific ASCT

Provide CD4 Help
Extend survival

Radio Therapies

Boost and Extend
Immune Abscopal effect

IL-7

CYT107

Vaccines

CD4 Help
Broaden Ag response
LT central memory T cells

Lymphopenic SEPSIS

Restore T cells counts and
functions to protect from
fatal Op. Infections

Invasive Fungal Infections

Expand a broad repertoire
of functional T cells
for Immune protection

Clinical Trials

Infectiology

Phase II 

Phase I 

Phase II 

       HIV: Phase II to determine the dose

HIV

       Sepsis: IRIS-7 early approach to treating sepsis

IRIS-7 AB

IRIS-7 CD

RESILIENT (Design)

Oncology

       Breast and Sarcoma: early evidences in oncology 

ELYPSE (Breast Carcinoma)

Pediatric Sarcoma

       Hematopoietic Stem Cell Transplant: first proof in hematology

T Cell Depleted HSCT

       Early Combination with Anti-PD1

CITN-1203 (Provenge Support)

CITN-14 (Urothelial Carcinoma)

CYT107 has an excellent safety profile

A good clinical
tolerance explained by

  • The natural human sequence

  • An optimized glycosylation profile

  • Similarity with endogenous IL-7

  • A self regulated receptor that vanishes with overactivation

Side effects

Most common

  • Injection site reactions

Less common to rare

  • Rash grade I/II

  • Transient elevation of liver enzymes

  • Transient respiratory distress

  • Active auto-immunity is a contraindication

Close to 600 patients treated

A systematic increase in lymphocyte counts across all studies and pathologies

Screen Shot 2023-02-27 at 9.13.07 PM.png
Screen Shot 2023-02-27 at 9.13.22 PM.png
bottom of page